Key result
Long-term phenylpropanolamine is linked to reversible ventricular hypertrophy in a canine case report.
Why the study?
Long-term phenylpropanolamine use and its association with myocardial hypertrophy in dogs had not been clearly documented.
Population
1 nine-year-old spayed female Dalmatian dog treated with phenylpropanolamine for almost 8.5 years
Comparison
Long-term phenylpropanolamine administration vs discontinuation of phenylpropanolamine
Design
Case report
Follow-up
1.5 years after surgery
Authors
Loading...
May warrant cardiac monitoring during long-term PPA in dogs; leaves open causal link to hypertrophy.
Case Report (n=1)
Long-term use of phenylpropanolamine in dogs may be associated with reversible myocardial hypertrophy and ventricular tachyarrhythmias.
Hanson et al. (2018) conducted a case report in Myocardial hypertrophy (n=1). Phenylpropanolamine (PPA) was evaluated on Ventricular hypertrophy. Long-term phenylpropanolamine administration in a dog was associated with ventricular hypertrophy, which resolved upon discontinuation and recurred upon resumption.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: